DOSE-SITE	of <RT_DOSE-START> 40 Gy <RT_DOSE-END> to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of <RT_DOSE-START> 40 Gy <RT_DOSE-END> to point A given in 1 to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of <RT_DOSE-START> 40 Gy <RT_DOSE-END> to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of <RT_DOSE-START> 40 Gy <RT_DOSE-END> to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of <RT_DOSE-START> 40 Gy <RT_DOSE-END> to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of <RT_DOSE-START> 81 Gy <RT_DOSE-END> to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
DOSE-SITE	of 40 Gy to point A given in 1 to 2 fractions for a total dose of <RT_DOSE-START> 81 Gy <RT_DOSE-END> to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of <RT_DOSE-START> 81 Gy <RT_DOSE-END> to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of <RT_DOSE-START> 81 Gy <RT_DOSE-END> to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of <RT_DOSE-START> 81 Gy <RT_DOSE-END> to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to <RT_DOSE-START> 30 to 35 Gy <RT_DOSE-END> delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to <RT_DOSE-START> 30 to 35 Gy <RT_DOSE-END> delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total
DOSE-SITE	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with <RT_DOSE-START> 30 to 35 Gy <RT_DOSE-END> delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with <RT_DOSE-START> 30 to 35 Gy <RT_DOSE-END> delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with <RT_DOSE-START> 30 to 35 Gy <RT_DOSE-END> delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total
None	of 40 Gy to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A <RT_DOSE-START> 30 Gy <RT_DOSE-END> to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A <RT_DOSE-START> 30 Gy <RT_DOSE-END> to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> <RT_DOSE-START> 30 Gy <RT_DOSE-END> to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
DOSE-SITE	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A <RT_DOSE-START> 30 Gy <RT_DOSE-END> to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A <RT_DOSE-START> 30 Gy <RT_DOSE-END> to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of <RT_DOSE-START> 75 Gy <RT_DOSE-END> 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of <RT_DOSE-START> 75 Gy <RT_DOSE-END> 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of <RT_DOSE-START> 75 Gy <RT_DOSE-END> 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of <RT_DOSE-START> 75 Gy <RT_DOSE-END> 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of <RT_DOSE-START> 75 Gy <RT_DOSE-END> 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to <Anatomical_site-START> point A <Anatomical_site-END> given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	of 40 Gy to point A given in 1 to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4
None	to 2 fractions for a total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and
None	to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and
None	to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and
None	to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and
None	to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and
None	to 2 fractions for a total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and
None	total dose of 81 Gy to <Anatomical_site-START> point A <Anatomical_site-END> with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then
None	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then
None	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then
DOSE-SITE	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then
None	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then
None	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then
None	total dose of 81 Gy to point A with cesium-137 , with 30 to 35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then
None	35 Gy delivered to <Anatomical_site-START> point A <Anatomical_site-END> 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to <Anatomical_site-START> point A <Anatomical_site-END> for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to
None	35 Gy delivered to point A 30 Gy to point A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel
None	A for a total dose of 75 Gy 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of <RT_DOSE-START> 45 Gy , <RT_DOSE-END> which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel
None	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
DOSE-SITE	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
DOSE-SITE	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
DOSE-SITE	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
None	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
None	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for
None	1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for
None	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
DOSE-SITE	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
DOSE-SITE	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
DOSE-SITE	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
None	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
None	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
None	fractions , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy )
None	Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
None	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
None	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
None	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
DOSE-SITE	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
DOSE-SITE	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
DOSE-SITE	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
None	Gy is limited to the tumor bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week
None	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
None	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
None	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
DOSE-SITE	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
DOSE-SITE	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
DOSE-SITE	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
None	bed . 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy , which is followed by a 1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( <RT_DOSE-START> 3.6 Gy <RT_DOSE-END> total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy
None	1.8 Gy x 3 fraction ( 5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy
None	5.4 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25
None	5.4 Gy total ) boost to the tumor bed and adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25
None	adjacent <Anatomical_site-START> lymph nodes , <Anatomical_site-END> and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	adjacent lymph nodes , and then optionally a 1.8 Gy x 2 fraction ( 3.6 Gy total ) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose
None	) <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads )
None	) boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads )
None	) boost to the tumor bed and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads )
None	) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads )
None	) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads )
None	) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads )
None	and a <Anatomical_site-START> 2 cm margin <Anatomical_site-END> if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given
None	and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given
DOSE-SITE	and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given
None	and a 2 cm margin if the small bowel could be avoided 1.80 Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last <RT_DOSE-START> 5.4 Gy <RT_DOSE-END> of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given
None	Gy for 25 fractions ( 45 Gy ) , with <Anatomical_site-START> boost <Anatomical_site-END> depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and
None	Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and
None	Gy for 25 fractions ( 45 Gy ) , with boost depending on stage 1.8 Gy fractions x 28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and
None	28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of <RT_DOSE-START> 4300 cGy <RT_DOSE-END> ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total
None	28 fractions given 5 days per week , for a total dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of <RT_DOSE-START> 4300 cGy <RT_DOSE-END> ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total
None	dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the <Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1
DOSE-SITE	dose of 50.4 Gy . The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1
None	<Anatomical_site-START> tumor bed <Anatomical_site-END> . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down boost of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of <RT_DOSE-START> 1720 cGy <RT_DOSE-END> ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9
DOSE-SITE	tumor bed . 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of <RT_DOSE-START> 1720 cGy <RT_DOSE-END> ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9
None	fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of <RT_DOSE-START> 6020 cGy <RT_DOSE-END> ( rads ) 1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4
None	1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~
None	1.8 Gy fractions x 28 fractions , total dose of 50.4 Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~
None	Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5
None	Gy to the planning target volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5
DOSE-SITE	volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with
DOSE-SITE	volume ( PTV-1 ) ; then a boost of 1.8 Gy fractions x 5 fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with
None	fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2
None	fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2
None	fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2
None	fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2
None	fractions , total boost dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2
None	dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an
None	dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an
None	dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an
None	dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an
None	dose of 9 Gy to the PTV-2 , for a total cumulative dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt
None	dose of 59.4 Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to 16 Gy to close (& lt
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm
None	Gy 1.80 Gy fractions x 25 fractions , for a total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to 16 Gy to close (& lt ; 5 mm
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to <Anatomical_site-START> close (& lt ; 5 mm ) <Anatomical_site-END> or positive margin areas of ( overall dose to these
None	total dose of 45 Gy , followed by 1.80 Gy x 3 fractions boost to the tumor bed ( total dose of 50.4 Gy ) 1.8 Gy fractions x 28 fractions , for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or <Anatomical_site-START> positive margin areas <Anatomical_site-END> of ( overall dose to these
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to <Anatomical_site-START> close (& lt ; 5 mm ) <Anatomical_site-END> or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
DOSE-SITE	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or <Anatomical_site-START> positive margin areas <Anatomical_site-END> of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
None	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ;
None	for a total dose of 50.4 Gy 1.7 Gy fractions x ~ 32 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of <RT_DOSE-START> 11 to 16 Gy <RT_DOSE-END> to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ;
None	5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to <Anatomical_site-START> primary site <Anatomical_site-END> and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to <Anatomical_site-START> close (& lt ; 5 mm ) <Anatomical_site-END> or positive margin areas of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or <Anatomical_site-START> positive margin areas <Anatomical_site-END> of ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	5 times per week , with boost to primary site and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> ) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8
None	and / or <Anatomical_site-START> cervical lymph nodes <Anatomical_site-END> with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
None	and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional <Anatomical_site-START> boost <Anatomical_site-END> dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
None	and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to <Anatomical_site-START> close (& lt ; 5 mm ) <Anatomical_site-END> or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
None	and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or <Anatomical_site-START> positive margin areas <Anatomical_site-END> of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
DOSE-SITE	and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
DOSE-SITE	and / or cervical lymph nodes with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of <RT_DOSE-START> 11 to 20 Gy <RT_DOSE-END> was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy
None	of 11 to 16 Gy to <Anatomical_site-START> close (& lt ; 5 mm ) <Anatomical_site-END> or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 74 Gy <RT_DOSE-END> ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the
None	of 11 to 16 Gy to close (& lt ; 5 mm ) or <Anatomical_site-START> positive margin areas <Anatomical_site-END> of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 74 Gy <RT_DOSE-END> ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the
None	of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 74 Gy <RT_DOSE-END> ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the
None	of 11 to 16 Gy to close (& lt ; 5 mm ) or positive margin areas of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to <RT_DOSE-START> 65 to 74 Gy <RT_DOSE-END> ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the
None	of ( overall dose to these sites : 65 to 70 Gy ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . <RT_DOSE-START> 180 cGy <RT_DOSE-END> x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0
None	of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . <RT_DOSE-START> 180 cGy <RT_DOSE-END> x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0
None	of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . <RT_DOSE-START> 180 cGy <RT_DOSE-END> x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0
None	of ( overall dose to these sites : 65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . <RT_DOSE-START> 180 cGy <RT_DOSE-END> x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0
None	65 to 70 Gy ) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions
None	65 to 70 Gy ) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions
None	65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions
None	65 to 70 Gy ) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions
None	) . A <Anatomical_site-START> boost <Anatomical_site-END> of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose :
None	) . A boost of 11 to 20 Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose :
None	) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose :
None	) . A boost of 11 to 20 Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose :
None	Gy was given to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week
None	Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week
None	Gy was given to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week
None	to <Anatomical_site-START> metastatic nodal sites <Anatomical_site-END> ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2
None	to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2
None	to metastatic nodal sites ( overall dose to these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2
DOSE-SITE	these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8
DOSE-SITE	these sites : 65 to 74 Gy ) ; see Bachaud et al . 1996 for details . 180 cGy x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8
None	x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of <RT_DOSE-START> 50.0 Gy <RT_DOSE-END> 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per
None	x 25 fractions ( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of <RT_DOSE-START> 50.0 Gy <RT_DOSE-END> 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per
None	( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5
None	( total of 45 Gy ) 1.8 Gy x 25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5
None	25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : <RT_DOSE-START> 60 Gy <RT_DOSE-END> ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5 fractions ( total dose : 20 Gy ) 2
None	25 fractions for a total of 45 Gy 2.0 Gy fractions x 15 fractions , then 2.0 Gy fractions x 10 fractions to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : <RT_DOSE-START> 60 Gy <RT_DOSE-END> ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 1.8 Gy x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5 fractions ( total dose : 20 Gy ) 2
None	to the initial <Anatomical_site-START> tumor length <Anatomical_site-END> plus a 5 cm margin , for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5 fractions ( total dose : 20 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 5 days per week 2.10 Gy fractions x
None	to the initial tumor length plus a <Anatomical_site-START> 5 cm margin , <Anatomical_site-END> for a total dose of 50.0 Gy 2 Gy fractions x 30 fractions ( total dose : 60 Gy ) , given 5 times per week on weeks 2 , 3 , 5 , 6 , 8 , 9 <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> x 25 fractions , for an initial dose of 40.8 Gy 4 Gy fractions once per day x 5 fractions ( total dose : 20 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 5 days per week 2.10 Gy fractions x
DOSE-SITE	. 3 Gy fractions twice per day , with the first fraction of each day given 1 to 2 hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for
DOSE-SITE	. 3 Gy fractions twice per day , with the first fraction of each day given 1 to 2 hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for
DOSE-SITE	. 3 Gy fractions twice per day , with the first fraction of each day given 1 to 2 hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for
None	hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy
None	hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy
None	hours after completion of chemotherapy and at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy
None	between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice
None	between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice
None	between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice
None	8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5
None	8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5
None	8 fractions , given on days 1 , 3 , 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5
None	, 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : <RT_DOSE-START> 50 Gy <RT_DOSE-END> ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy
None	, 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : <RT_DOSE-START> 50 Gy <RT_DOSE-END> ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy
None	, 15 , 17 ( total induction dose : 24 Gy ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : <RT_DOSE-START> 50 Gy <RT_DOSE-END> ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy
None	( total induction dose : 24 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> , bladder tumor volume , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy ) 1.8 Gy
None	( total induction dose : 24 Gy ) , administered to the whole bladder , <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy ) 1.8 Gy
None	( total induction dose : 24 Gy ) , administered to the whole bladder , bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 50 Gy 1.7 Gy x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy ) 1.8 Gy
None	<Anatomical_site-START> bladder tumor volume <Anatomical_site-END> , and pelvic lymph nodes . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy ) 1.8 Gy fractions given 5 times per week ( total dose : 70 Gy ) 1.8
None	bladder tumor volume , and <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> . 1.8 Gy fractions x 25 fractions ( total dose of 45 Gy ) 2.0 Gy x 25 fractions ( total dose : 50 Gy ) 2.0 Gy fractions x 25 fractions , for a total dose of 50 Gy <RT_DOSE-START> 1.7 Gy <RT_DOSE-END> x 30 fractions , for an initial dose of 51 Gy 1.1 Gy fractions x 70 fractions , given twice per day , 5 times per week ( total dose : 77 Gy ) 1.8 Gy fractions given 5 times per week ( total dose : 70 Gy ) 1.8
None	fractions ) x 30 fractions ( total dose : 45 Gy ) over 3 weeks , started on cycle 1 day 2 of chemotherapy 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy . 1.7 Gy x 29 fractions , for a total dose of <RT_DOSE-START> 49.3 Gy <RT_DOSE-END> , starting on cycle 1 day 1 1.8 Gy per day x 28 fractions ( total dose : 50.4 Gy ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of
None	Gy ) over 3 weeks , started on cycle 1 day 2 of chemotherapy 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy . 1.7 Gy x 29 fractions , for a total dose of 49.3 Gy , starting on cycle 1 day 1 <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> per day x 28 fractions ( total dose : 50.4 Gy ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions ,
None	2 of chemotherapy 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy . 1.7 Gy x 29 fractions , for a total dose of 49.3 Gy , starting on cycle 1 day 1 1.8 Gy per day x 28 fractions ( total dose : <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy (
None	1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy . 1.7 Gy x 29 fractions , for a total dose of 49.3 Gy , starting on cycle 1 day 1 1.8 Gy per day x 28 fractions ( total dose : 50.4 Gy ) <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and
None	29 fractions , for a total dose of 49.3 Gy , starting on cycle 1 day 1 1.8 Gy per day x 28 fractions ( total dose : 50.4 Gy ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of <RT_DOSE-START> 4300 cGy <RT_DOSE-END> ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 200 cGy fractions x 4 doses ( 8
DOSE-SITE	starting on cycle 1 day 1 1.8 Gy per day x 28 fractions ( total dose : 50.4 Gy ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of <RT_DOSE-START> 172 cGy <RT_DOSE-END> ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 200 cGy fractions x 4 doses ( 8 Gy total ) in 2 Gy fractions once per day
DOSE-SITE	50.4 Gy ) 172 cGy ( rads ) fractions x 25 fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of <RT_DOSE-START> 1720 cGy <RT_DOSE-END> ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 200 cGy fractions x 4 doses ( 8 Gy total ) in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 850 to 1020 cGy in
None	fractions , given over 5 weeks for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of <RT_DOSE-START> 6020 cGy <RT_DOSE-END> ( rads ) 200 cGy fractions x 4 doses ( 8 Gy total ) in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 850 to 1020 cGy in 5 to 6 fractions delivered on days - 3 to - 1
None	for a total dose of 4300 cGy ( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) <RT_DOSE-START> 200 cGy <RT_DOSE-END> fractions x 4 doses ( 8 Gy total ) in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 850 to 1020 cGy in 5 to 6 fractions delivered on days - 3 to - 1 1.8 Gy fractions x 28
None	( 4300 rads ) , then coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 200 cGy fractions x 4 doses ( <RT_DOSE-START> 8 Gy <RT_DOSE-END> total ) in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 850 to 1020 cGy in 5 to 6 fractions delivered on days - 3 to - 1 1.8 Gy fractions x 28 fractions ( total dose 2 Gy
None	coned-down <Anatomical_site-START> boost <Anatomical_site-END> of 172 cGy ( rads ) fractions x 10 fractions , given over 2 weeks for a dose of 1720 cGy ( rads ) , and a total cumulative dose of 6020 cGy ( rads ) 200 cGy fractions x 4 doses ( 8 Gy total ) in <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions once per day x 4 = total dose of 8 Gy , without lung shielding 850 to 1020 cGy in 5 to 6 fractions delivered on days - 3 to - 1 1.8 Gy fractions x 28 fractions ( total dose 2 Gy fractions x 25 fractions ( total
None	35 Gy 5.0 Gy once per day for a total of 5 fractions ( total dose : 25 Gy ) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . <RT_DOSE-START> 2.10 Gy <RT_DOSE-END> fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or
None	35 Gy 5.0 Gy once per day for a total of 5 fractions ( total dose : 25 Gy ) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . <RT_DOSE-START> 2.10 Gy <RT_DOSE-END> fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or
None	) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : <RT_DOSE-START> 52.5 Gy <RT_DOSE-END> ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy )
None	) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : <RT_DOSE-START> 52.5 Gy <RT_DOSE-END> ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy )
None	) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : <RT_DOSE-START> 52.5 Gy <RT_DOSE-END> ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy )
None	) 2 Gy fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : <RT_DOSE-START> 52.5 Gy <RT_DOSE-END> ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy )
None	fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given
None	fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given
None	fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given
None	fractions x 33 fractions ( total dose : 66 Gy ) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given
None	) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose :
None	) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose :
None	) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose :
None	) . See Chan et al . 2005 for additional information about boost doses . 2.10 Gy fractions x 25 fractions over 5 weeks , given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : <RT_DOSE-START> 54 Gy <RT_DOSE-END> ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose :
DOSE-SITE	, given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions (
DOSE-SITE	, given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions (
DOSE-SITE	, given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions (
DOSE-SITE	, given during cycle 1 of chemotherapy ( total dose : 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions (
DOSE-SITE	: 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 <RT_DOSE-START> 12 Gy ) <RT_DOSE-END> 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy
DOSE-SITE	: 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 <RT_DOSE-START> 12 Gy ) <RT_DOSE-END> 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy
DOSE-SITE	: 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 <RT_DOSE-START> 12 Gy ) <RT_DOSE-END> 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy
DOSE-SITE	: 52.5 Gy ) 2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 <RT_DOSE-START> 12 Gy ) <RT_DOSE-END> 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy
None	2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) <RT_DOSE-START> 1.5 Gy <RT_DOSE-END> fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions
None	2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) <RT_DOSE-START> 1.5 Gy <RT_DOSE-END> fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions
None	2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) <RT_DOSE-START> 1.5 Gy <RT_DOSE-END> fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions
None	2 Gy fractions x 27 fractions ( total dose : 54 Gy ) , given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) <RT_DOSE-START> 1.5 Gy <RT_DOSE-END> fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions
None	, given 5 times per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions
None	, given 5 times per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions
None	, given 5 times per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions
None	, given 5 times per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : <RT_DOSE-START> 24 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions
None	per week , with <Anatomical_site-START> boost <Anatomical_site-END> to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose :
None	per week , with boost to <Anatomical_site-START> areas at high risk <Anatomical_site-END> for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose :
None	per week , with boost to areas at high risk for malignant dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose :
None	per week , with boost to areas at high risk for malignant dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose :
None	dissemination or that had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 6 times per week 2.25 Gy
None	dissemination or that had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2.00 Gy x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 6 times per week 2.25 Gy
None	had <Anatomical_site-START> inadequate resection margins <Anatomical_site-END> of 2 Gy fractions x 6 fractions ( boost dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 6 times per week 2.25 Gy fractions x 20
None	had inadequate resection margins of 2 Gy fractions x 6 fractions ( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> x 34 to 35 fractions ( total dose of 68 to 70 Gy ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 6 times per week 2.25 Gy fractions x 20
None	( <Anatomical_site-START> boost <Anatomical_site-END> dose : 12 Gy ) 1.5 Gy fractions given twice per day x 16 fractions ( total dose : 24 Gy ) 1.8 Gy fractions x 25 fractions , for a total dose of 45 Gy 2.00 Gy x 34 to 35 fractions ( total dose of 68 to <RT_DOSE-START> 68 to 70 Gy <RT_DOSE-END> ) 1.8 Gy x 25 fractions ( total dose : 45 Gy ) 2 Gy fractions x 35 fractions ( total dose : 70 Gy ) , given 6 times per week 2.25 Gy fractions x 20 fractions ( total dose of 45 Gy ) 2 Gy fractions x
None	x 15 fractions , for a total dose of 40.05 Gy 1.8 Gy for 33 fractions ( total dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : <RT_DOSE-START> 66-70 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed
None	x 15 fractions , for a total dose of 40.05 Gy 1.8 Gy for 33 fractions ( total dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : <RT_DOSE-START> 66-70 Gy <RT_DOSE-END> ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END>
None	for a total dose of 40.05 Gy 1.8 Gy for 33 fractions ( total dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy +
None	for a total dose of 40.05 Gy 1.8 Gy for 33 fractions ( total dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy +
None	dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of <RT_DOSE-START> 36 to 39.6 Gy <RT_DOSE-END> , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33
None	dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of <RT_DOSE-START> 36 to 39.6 Gy <RT_DOSE-END> , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33
None	dose of 59.4 Gy ) 2 Gy fractions x 30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of <RT_DOSE-START> 36 to 39.6 Gy <RT_DOSE-END> , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33
None	30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy )
None	30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy )
None	30 fractions , for a total dose of 60 Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy )
None	Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9
None	Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9
None	Gy 2.0 Gy fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9
None	fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the
None	fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the
None	fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the
None	fractions given 5 times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the
None	times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed
None	times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed
None	times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed
None	times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed
None	times per week ( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END>
DOSE-SITE	( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy
DOSE-SITE	( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy
None	( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy
None	( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy
None	( total dose : 66-70 Gy ) 1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to
None	1.8 Gy fractions x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed <RT_DOSE-START> 50 Gy <RT_DOSE-END> + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed
DOSE-SITE	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed
None	x 20 to 22 fractions , for an initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + <RT_DOSE-START> 20 Gy <RT_DOSE-END> boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END>
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x
None	initial total dose of 36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	36 to 39.6 Gy , started on day 8 1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions
None	1.80 Gy x 28 fractions , total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : <RT_DOSE-START> 66 Gy <RT_DOSE-END> ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	, total dose of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	of 50.4 Gy to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
DOSE-SITE	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
DOSE-SITE	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 9 Gy <RT_DOSE-END> boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial
None	Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then
None	Gy boost to the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to <RT_DOSE-START> 30 Gy <RT_DOSE-END> in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then
None	the <Anatomical_site-START> tumor bed <Anatomical_site-END> 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional
None	the tumor bed 50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional
None	50 Gy + 20 Gy <Anatomical_site-START> boost <Anatomical_site-END> ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
DOSE-SITE	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
DOSE-SITE	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate
None	50 Gy + 20 Gy boost ( total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus <RT_DOSE-START> 10 Gy <RT_DOSE-END> boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END>
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65
None	total dose minimum of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed <RT_DOSE-START> 45 Gy <RT_DOSE-END> in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy
None	of 70 Gy ) 2.00 Gy fractions x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in <RT_DOSE-START> 1.80 Gy <RT_DOSE-END> fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
DOSE-SITE	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	x 33 fractions ( total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then <RT_DOSE-START> 18 Gy <RT_DOSE-END> boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
DOSE-SITE	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	total dose : 66 Gy ) to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
DOSE-SITE	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) ,
None	to the <Anatomical_site-START> tumor bed <Anatomical_site-END> to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy <Anatomical_site-START> boost <Anatomical_site-END> to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the <Anatomical_site-START> tumor bed <Anatomical_site-END> 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
DOSE-SITE	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	to the tumor bed to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed 45 Gy in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial <RT_DOSE-START> 44 to 46 Gy <RT_DOSE-END> to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy )
None	in 1.80 Gy fractions x 25 fractions , then 18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy
None	in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy
DOSE-SITE	in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy
DOSE-SITE	in 1.80 Gy fractions x 25 fractions , then 18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to <RT_DOSE-START> 65 to 70 Gy <RT_DOSE-END> in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy
None	18 Gy <Anatomical_site-START> boost <Anatomical_site-END> in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to <RT_DOSE-START> 60 to 65 Gy <RT_DOSE-END> total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily
None	18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to <RT_DOSE-START> 60 to 65 Gy <RT_DOSE-END> total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily
DOSE-SITE	18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to <RT_DOSE-START> 60 to 65 Gy <RT_DOSE-END> total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily
DOSE-SITE	18 Gy boost in 2.00 Gy fractions x 9 fractions 1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to <RT_DOSE-START> 60 to 65 Gy <RT_DOSE-END> total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily
None	1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single
None	1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single
None	1.8 to 2 Gy per fraction , with an initial 44 to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single
None	to 46 Gy to the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up
None	to 46 Gy to the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up
None	to 46 Gy to the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up
None	to 46 Gy to the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week <RT_DOSE-START> 45 Gy <RT_DOSE-END> ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up
None	the <Anatomical_site-START> pelvis <Anatomical_site-END> , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions
None	the pelvis , then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions
None	the pelvis , then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions
None	the pelvis , then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions
None	then an additional <Anatomical_site-START> boost <Anatomical_site-END> to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions per patient ,
None	then an additional boost to the <Anatomical_site-START> prostate <Anatomical_site-END> that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions per patient ,
None	then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient ,
None	a total dose of 65 to 70 Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose
None	Gy in definitive radiation patients ; 60 to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was <RT_DOSE-START> 36 Gy <RT_DOSE-END> in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy
None	to 65 Gy total dose for post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions <RT_DOSE-START> 36 Gy <RT_DOSE-END> in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total
None	post-prostatectomy patients 58 to 66 Gy ) , given 5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions <RT_DOSE-START> 1.80-Gy <RT_DOSE-END> fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions (
DOSE-SITE	5 days per week 45 Gy ) 36 Gy in 2.00 Gy fractions , 5 days per week at 50.4 Gy in 28 fractions . was 36 Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of <RT_DOSE-START> 8 Gy <RT_DOSE-END> per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to
None	Gy in 15 daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4
None	daily fractions 36 Gy in daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to <RT_DOSE-START> 10 to 12 Gy <RT_DOSE-END> total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given
None	daily fractions 1.80-Gy fractions given focally at a single dose of 8 Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total <RT_DOSE-START> 1200 cGy <RT_DOSE-END> in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary
None	Gy per target <Anatomical_site-START> bone lesion <Anatomical_site-END> for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to <RT_DOSE-START> 45 to 50.4 Gy <RT_DOSE-END> total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to
None	Gy per target bone lesion for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) <RT_DOSE-START> 45 to 50.4 Gy <RT_DOSE-END> total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to
None	Gy per target bone lesion for up to three bone lesions per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) <RT_DOSE-START> 45 to 50.4 Gy <RT_DOSE-END> total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to
None	per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions <RT_DOSE-START> 45 Gy <RT_DOSE-END> total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) .
None	per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions <RT_DOSE-START> 45 Gy <RT_DOSE-END> total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) .
None	per patient , given 24 to 48 h before the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions <RT_DOSE-START> 45 Gy <RT_DOSE-END> total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) .
None	the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of <RT_DOSE-START> 50 Gy <RT_DOSE-END> given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total
None	the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of <RT_DOSE-START> 50 Gy <RT_DOSE-END> given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total
None	the first ipilimumab dose with a total dose of 60 Gy 10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of <RT_DOSE-START> 50 Gy <RT_DOSE-END> given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total
DOSE-SITE	10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for
DOSE-SITE	10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for
None	10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for
None	10 to 12 Gy total 1200 cGy in fractions ( pulmonary dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for
DOSE-SITE	dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70
DOSE-SITE	dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70
None	dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70
None	dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70
None	dosage was limited to 800 cGy ) 45 to 50.4 Gy total in 25 to 28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; <RT_DOSE-START> 30 to 40 Gy <RT_DOSE-END> to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk ,
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk ,
DOSE-SITE	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk ,
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk ,
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk ,
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk ,
None	28 fractions 45 Gy total in 25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( <RT_DOSE-START> 70 to 74 Gy <RT_DOSE-END> ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> ,
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving
None	25 fractions total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . <RT_DOSE-START> 64 Gy <RT_DOSE-END> 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8
None	total of 50 Gy given in 25 fractions with cycles 3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy <RT_DOSE-START> 54 Gy <RT_DOSE-END> Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8
None	3 and 4 30 to 40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
DOSE-SITE	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	3 and 4 30 to 40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is <RT_DOSE-START> 50 Gy <RT_DOSE-END> for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from
None	40 Gy given to sites of <Anatomical_site-START> primary bulky disease <Anatomical_site-END> ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
DOSE-SITE	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	40 Gy given to sites of primary bulky disease ; 30 to 40 Gy to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; <RT_DOSE-START> 66 Gy <RT_DOSE-END> for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30
None	to <Anatomical_site-START> primary extranodal disease <Anatomical_site-END> at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to <Anatomical_site-START> primary tumor <Anatomical_site-END> ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
DOSE-SITE	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy .
None	to primary extranodal disease at physician discretion to primary tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; <RT_DOSE-START> 70 Gy <RT_DOSE-END> for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy .
None	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or
None	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or
None	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or
DOSE-SITE	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or
None	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or
None	tumor ( 70 to 74 Gy ) . 64 Gy 54 Gy Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . <RT_DOSE-START> 60 Gy <RT_DOSE-END> to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or
None	Minimum total dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
None	Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
None	Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
None	Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
DOSE-SITE	Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
None	Minimum total dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least <RT_DOSE-START> 44.8 Gy <RT_DOSE-END> 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to
None	dose to <Anatomical_site-START> neck nodes <Anatomical_site-END> is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	dose to neck nodes is 50 Gy for N0 disease ; 66 Gy for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy
None	for <Anatomical_site-START> nodes less than or equal to 2 cm <Anatomical_site-END> in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 <RT_DOSE-START> 30 Gy <RT_DOSE-END> total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy )
None	for nodes less than or equal to 2 cm in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 <RT_DOSE-START> 30 Gy <RT_DOSE-END> total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy )
None	for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 <RT_DOSE-START> 30 Gy <RT_DOSE-END> total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy )
None	for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 <RT_DOSE-START> 30 Gy <RT_DOSE-END> total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy )
None	for nodes less than or equal to 2 cm in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 <RT_DOSE-START> 30 Gy <RT_DOSE-END> total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy )
None	in size ; 70 Gy for <Anatomical_site-START> nodes greater than 2 cm <Anatomical_site-END> . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to <RT_DOSE-START> 64 to 66 Gy <RT_DOSE-END> . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with
None	in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the <Anatomical_site-START> tumor bulk <Anatomical_site-END> , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to <RT_DOSE-START> 64 to 66 Gy <RT_DOSE-END> . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with
None	in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the <Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to <RT_DOSE-START> 64 to 66 Gy <RT_DOSE-END> . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with
DOSE-SITE	in size ; 70 Gy for nodes greater than 2 cm . 60 Gy to the tumor bulk , with the tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to <RT_DOSE-START> 64 to 66 Gy <RT_DOSE-END> . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with
None	<Anatomical_site-START> tumor-bearing compartment <Anatomical_site-END> receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the bladder of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . <RT_DOSE-START> 40 Gy <RT_DOSE-END> in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to
None	tumor-bearing compartment receiving at least 44.8 Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . <RT_DOSE-START> 40 Gy <RT_DOSE-END> in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to
None	Gy 24 Gy total given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to <RT_DOSE-START> 1.80 to 2.00 Gy <RT_DOSE-END> 1.2 Gy twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to 72 Gy at 180 to 200 cGy per
None	given in 10 fractions from days 1 to 12 30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy <RT_DOSE-START> 1.2 Gy <RT_DOSE-END> twice per day fractions ( total dose : 69.6 Gy ) 2 Gy fractions given 5 days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to 72 Gy at 180 to 200 cGy per day 64.8
None	30 Gy total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> of 64 to 66 Gy . No further details given about fractionation , schedule , or dose to lymph nodes . 40 Gy in daily fractions of 1.80 to 2.00 Gy 1.2 Gy twice per day fractions ( total dose : <RT_DOSE-START> 69.6 Gy <RT_DOSE-END> ) 2 Gy fractions given 5 days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to 72 Gy at 180 to 200 cGy per day 64.8 Gy in 36 daily fractions of 1.80 Gy 2
None	days per week , with total bladder dose of 60 Gy . Total dose to regional lymph nodes 60 Gy 68 to 72 Gy at 180 to 200 cGy per day 64.8 Gy in 36 daily fractions of 1.80 Gy 2 Gy fractions ( total dose : <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 days per week in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in
None	Total dose to regional lymph nodes 60 Gy 68 to 72 Gy at 180 to 200 cGy per day 64.8 Gy in 36 daily fractions of 1.80 Gy 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 days per week in <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions once per day x 4 = total dose of 8 Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions 2 Gy 18 Gy ( details not
None	72 Gy at 180 to 200 cGy per day 64.8 Gy in 36 daily fractions of 1.80 Gy 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 days per week in 2 Gy fractions once per day x 4 = total dose of <RT_DOSE-START> 8 Gy <RT_DOSE-END> , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions 2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to
None	per day 64.8 Gy in 36 daily fractions of 1.80 Gy 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 days per week in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding <RT_DOSE-START> 1.8 to 2.0 Gy <RT_DOSE-END> fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions 2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for
DOSE-SITE	66 Gy ) , given 5 days per week in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , <RT_DOSE-START> 50.4 Gy <RT_DOSE-END> in 28 fractions 2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4
None	days per week in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2
None	in 2 Gy fractions once per day x 4 = total dose of 8 Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions 2 Gy <RT_DOSE-START> 18 Gy <RT_DOSE-END> ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a
None	Gy , without lung shielding 1.8 to 2.0 Gy fractions , to start within 24 hours of the start of chemotherapy to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 50.4 Gy in 28 fractions 2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to <RT_DOSE-START> 1.8 to 2.0 Gy <RT_DOSE-END> once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in
None	50.4 Gy in 28 fractions 2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of <RT_DOSE-START> 46.0 to 50.4 Gy <RT_DOSE-END> 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week .
None	2 Gy 18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy <RT_DOSE-START> 45 Gy <RT_DOSE-END> 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions
None	18 Gy ( details not provided ) given during cycles 2 to 4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy <RT_DOSE-START> 2 Gy <RT_DOSE-END> at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose
None	4 : 1.8 to 2.0 Gy once per day Monday through Friday for a total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 <RT_DOSE-START> 60 Gy <RT_DOSE-END> , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week
DOSE-SITE	total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy
None	total of 23 to 28 fractions over 5 to 6 weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the primary tumor , <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy
DOSE-SITE	weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : <RT_DOSE-START> 40 Gy <RT_DOSE-END> ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day ,
None	weeks and a total dose of 46.0 to 50.4 Gy 45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the primary tumor , 1.8 to 2 Gy fractions ( median total dose : <RT_DOSE-START> 40 Gy <RT_DOSE-END> ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day ,
None	45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . <RT_DOSE-START> 1.20 Gy <RT_DOSE-END> fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy )
None	45 Gy 2 Gy at a rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the primary tumor , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . <RT_DOSE-START> 1.20 Gy <RT_DOSE-END> fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy )
None	rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the <Anatomical_site-START> primary tumor <Anatomical_site-END> , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : <RT_DOSE-START> 69.6 Gy <RT_DOSE-END> ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily
None	rate of 0.07 Gy / min on day 0 60 Gy , details not available in abstract to the primary tumor , 1.8 to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : <RT_DOSE-START> 69.6 Gy <RT_DOSE-END> ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily
DOSE-SITE	to 2 Gy fractions ( median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to <RT_DOSE-START> 40 to 50 Gy <RT_DOSE-END> 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions
None	median total dose : 40 Gy ) , given 5 times per week . 1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy <RT_DOSE-START> 2.0 Gy <RT_DOSE-END> fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy
None	1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage
None	1.20 Gy fractions ( total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : <RT_DOSE-START> 70 Gy <RT_DOSE-END> ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage
None	total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to <RT_DOSE-START> 46 to 50 Gy <RT_DOSE-END> in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy
None	total dose : 69.6 Gy ) , given twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) <RT_DOSE-START> 46 to 50 Gy <RT_DOSE-END> in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy
None	twice per day for 5 days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to <RT_DOSE-START> 1.80 to 2.00 Gy <RT_DOSE-END> 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details .
None	twice per day for 5 days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of <RT_DOSE-START> 1.80 to 2.00 Gy <RT_DOSE-END> 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details .
None	days per week , starting on cycle 1 day 1 to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250
None	days per week , starting on cycle 1 day 1 to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy <RT_DOSE-START> 1.8 Gy <RT_DOSE-END> fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250
None	to the <Anatomical_site-START> pelvis <Anatomical_site-END> , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy
None	to the pelvis , 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of <RT_DOSE-START> 45 Gy <RT_DOSE-END> 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy
None	, 40 to 50 Gy 2.0 Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy <RT_DOSE-START> 66 Gy <RT_DOSE-END> in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated
None	Gy fractions once per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of <RT_DOSE-START> 2 Gy <RT_DOSE-END> 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5
DOSE-SITE	per day , 5 times per week ( total dose : 70 Gy ) 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy 1.8 Gy fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy <RT_DOSE-START> 25 to 30 Gy <RT_DOSE-END> to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day
None	fractions x 25 fractions for a total dose of 45 Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in <RT_DOSE-START> 250 cGy <RT_DOSE-END> fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose :
None	Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : <RT_DOSE-START> 25 Gy <RT_DOSE-END> ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and
None	Gy 66 Gy in 33 daily fractions of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : <RT_DOSE-START> 25 Gy <RT_DOSE-END> ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and
None	of 2 Gy 25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose <RT_DOSE-START> 70.6 Gy <RT_DOSE-END> 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose
None	of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose <RT_DOSE-START> 70.6 Gy <RT_DOSE-END> 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose
None	of 2 Gy 25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose <RT_DOSE-START> 70.6 Gy <RT_DOSE-END> 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose
None	25 to 30 Gy to the <Anatomical_site-START> contralateral testis <Anatomical_site-END> . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy <RT_DOSE-START> 2.5 Gy <RT_DOSE-END> fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole
DOSE-SITE	25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy <RT_DOSE-START> 2.5 Gy <RT_DOSE-END> fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose to the whole
DOSE-SITE	25 to 30 Gy to the contralateral testis . For patients with stage II disease , involved-field radiation therapy was added ; see paper for details . in 250 cGy fractions x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy <RT_DOSE-START> 2.5 Gy <RT_DOSE-END> fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose to the whole
DOSE-SITE	x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : <RT_DOSE-START> 20 Gy <RT_DOSE-END> ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per
DOSE-SITE	x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : <RT_DOSE-START> 20 Gy <RT_DOSE-END> ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per
None	x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : <RT_DOSE-START> 20 Gy <RT_DOSE-END> ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per
None	x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : <RT_DOSE-START> 20 Gy <RT_DOSE-END> ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per
None	x 10 fractions ( total dose : 25 Gy ) hyperfractionated to total dose 70.6 Gy 2.5 Gy fractions twice per day , with at least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : <RT_DOSE-START> 20 Gy <RT_DOSE-END> ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per
None	least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was <RT_DOSE-START> 44 Gy <RT_DOSE-END> in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per
None	least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose to the whole bladder and bladder tumor volume was <RT_DOSE-START> 44 Gy <RT_DOSE-END> in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per
DOSE-SITE	least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was <RT_DOSE-START> 44 Gy <RT_DOSE-END> in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per
DOSE-SITE	least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was <RT_DOSE-START> 44 Gy <RT_DOSE-END> in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per
None	least 4 hours between fractions , x 8 fractions , given on days 1 , 3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was <RT_DOSE-START> 44 Gy <RT_DOSE-END> in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per
None	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 ,
None	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 ,
None	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 ,
None	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 ,
DOSE-SITE	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 ,
None	3 , 15 , 17 ( total consolidation dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was <RT_DOSE-START> 24 Gy <RT_DOSE-END> in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 ,
None	dose : 20 Gy ) , administered to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder
None	dose : 20 Gy ) , administered to the whole bladder and bladder tumor volume . The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in <RT_DOSE-START> 3 Gy <RT_DOSE-END> fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END>
None	The total dose to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days
None	The total dose to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days
None	The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days
None	The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days
None	The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days
None	The total dose to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of <RT_DOSE-START> 12 Gy <RT_DOSE-END> 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days
None	to the whole <Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20
None	to the whole bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20
None	to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20
None	to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20
None	to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20
None	to the whole bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy <RT_DOSE-START> 20 Gy <RT_DOSE-END> 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20
None	<Anatomical_site-START> bladder <Anatomical_site-END> and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy
None	bladder and <Anatomical_site-START> bladder tumor volume <Anatomical_site-END> was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy
None	bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy
None	bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy
None	bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy
None	bladder and bladder tumor volume was 44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy <RT_DOSE-START> 40 Gy <RT_DOSE-END> in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy
None	44 Gy in 16 fractions ; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8
None	44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8
None	44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8
None	44 Gy in 16 fractions ; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8
None	; the total dose to the <Anatomical_site-START> pelvic lymph nodes <Anatomical_site-END> was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for
DOSE-SITE	; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for
None	; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for
None	; the total dose to the pelvic lymph nodes was 24 Gy in 8 fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for
None	fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions
DOSE-SITE	fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions
None	fractions . in 3 Gy fractions once per day on days - 6 to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions
None	to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given
None	to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given
DOSE-SITE	to - 3 = total dose of 12 Gy 20 Gy 40 Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then <RT_DOSE-START> 2 Gy <RT_DOSE-END> per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given
None	Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 <RT_DOSE-START> 30 Gy <RT_DOSE-END> ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to
None	Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 <RT_DOSE-START> 30 Gy <RT_DOSE-END> ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to
None	Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 <RT_DOSE-START> 30 Gy <RT_DOSE-END> ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to
None	Gy in 20 fractions of 2.00 Gy per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 <RT_DOSE-START> 30 Gy <RT_DOSE-END> ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to
None	per fraction 2 Gy per day to the <Anatomical_site-START> pelvis <Anatomical_site-END> on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites ,
None	per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites ,
None	per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites ,
None	per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites ,
None	per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites ,
None	per fraction 2 Gy per day to the pelvis on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with <RT_DOSE-START> 1.8 to 2 Gy <RT_DOSE-END> fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> ,
None	on days 1 to 10 , then 2 Gy per day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x
None	on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x
None	on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x
None	on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x
None	on days 1 to 10 , then 2 Gy per day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x
None	day to the <Anatomical_site-START> bladder <Anatomical_site-END> on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for
None	day to the bladder on days 11 to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for
None	day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for
None	day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for
None	day to the bladder on days 11 to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions <RT_DOSE-START> 2 Gy <RT_DOSE-END> fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for
None	to 14 , then 2 Gy per day to the <Anatomical_site-START> bladder tumor <Anatomical_site-END> on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to
None	to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to
None	to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to
None	to 14 , then 2 Gy per day to the bladder tumor on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : <RT_DOSE-START> 58 to 66 Gy <RT_DOSE-END> ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to
DOSE-SITE	on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week <RT_DOSE-START> 40 Gy <RT_DOSE-END> to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6
None	on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week <RT_DOSE-START> 40 Gy <RT_DOSE-END> to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6
None	on days 15 to 20 30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week <RT_DOSE-START> 40 Gy <RT_DOSE-END> to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6
None	30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , <RT_DOSE-START> 30.6 Gy <RT_DOSE-END> to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to
DOSE-SITE	30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , <RT_DOSE-START> 30.6 Gy <RT_DOSE-END> to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to
None	30 Gy ( see note ) with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , <RT_DOSE-START> 30.6 Gy <RT_DOSE-END> to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to
None	with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites <RT_DOSE-START> 36 Gy <RT_DOSE-END> to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in
None	with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> <RT_DOSE-START> 36 Gy <RT_DOSE-END> to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in
DOSE-SITE	with 1.8 to 2 Gy fractions for a total dose of 60 Gy to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites <RT_DOSE-START> 36 Gy <RT_DOSE-END> to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in
None	to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction
None	to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction
None	to 50.4 Gy in 28 fractions 2 Gy fractions ( total dose : 58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x <RT_DOSE-START> 2.00 Gy <RT_DOSE-END> fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction
None	58 to 66 Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8
None	58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8
None	58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8
None	58 to 66 Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of <RT_DOSE-START> 60 Gy <RT_DOSE-END> 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8
None	Gy ) , given 5 times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to <RT_DOSE-START> 24 to 36 Gy <RT_DOSE-END> 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to
None	Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to <RT_DOSE-START> 24 to 36 Gy <RT_DOSE-END> 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to
None	Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to <RT_DOSE-START> 24 to 36 Gy <RT_DOSE-END> 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to
None	Gy ) , given 5 times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy <RT_DOSE-START> 24 to 36 Gy <RT_DOSE-END> 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to
None	times per week 40 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is
None	times per week 40 Gy to involved sites , 30.6 Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is
None	times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is
None	times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is
None	times per week 40 Gy to involved sites , 30.6 Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy <RT_DOSE-START> 24 Gy <RT_DOSE-END> 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is
None	Gy to <Anatomical_site-START> uninvolved sites <Anatomical_site-END> 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to <RT_DOSE-START> 40 to 44 Gy <RT_DOSE-END> 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy
None	Gy to uninvolved sites 36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to <RT_DOSE-START> 40 to 44 Gy <RT_DOSE-END> 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy
None	Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) <RT_DOSE-START> 40 to 44 Gy <RT_DOSE-END> 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy
None	Gy to uninvolved sites 36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) <RT_DOSE-START> 40 to 44 Gy <RT_DOSE-END> 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy
None	36 Gy to <Anatomical_site-START> involved sites <Anatomical_site-END> , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy <RT_DOSE-START> 21 Gy <RT_DOSE-END> in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total
None	36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy <RT_DOSE-START> 21 Gy <RT_DOSE-END> in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total
None	36 Gy to involved sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy <RT_DOSE-START> 21 Gy <RT_DOSE-END> in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total
None	sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of <RT_DOSE-START> 1.50 to 1.75 Gy <RT_DOSE-END> per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	sites , 30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of <RT_DOSE-START> 1.50 to 1.75 Gy <RT_DOSE-END> per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
DOSE-SITE	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is <RT_DOSE-START> 64.8 Gy <RT_DOSE-END> ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is <RT_DOSE-START> 64.8 Gy <RT_DOSE-END> ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is <RT_DOSE-START> 45.6 Gy <RT_DOSE-END> . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
DOSE-SITE	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is <RT_DOSE-START> 45.6 Gy <RT_DOSE-END> . 20 Gy in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . <RT_DOSE-START> 20 Gy <RT_DOSE-END> in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . <RT_DOSE-START> 20 Gy <RT_DOSE-END> in 5 fractions 54.4 Gy for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions <RT_DOSE-START> 54.4 Gy <RT_DOSE-END> for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions <RT_DOSE-START> 54.4 Gy <RT_DOSE-END> for a total dose of 61.2 Gy
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the <Anatomical_site-START> bladder <Anatomical_site-END> is 64.8 Gy ; total dose to lymph nodes is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of <RT_DOSE-START> 61.2 Gy <RT_DOSE-END>
None	30.6 Gy to uninvolved sites 30 x 2.00 Gy fractions , five days per week , for a total dose of 60 Gy 24 to 36 Gy 24 Gy 30 Gy (+ 6 Gy boost ) 40 to 44 Gy 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction After induction radiation therapy and consolidation radiation therapy , total dose to the bladder is 64.8 Gy ; total dose to <Anatomical_site-START> lymph nodes <Anatomical_site-END> is 45.6 Gy . 20 Gy in 5 fractions 54.4 Gy for a total dose of <RT_DOSE-START> 61.2 Gy <RT_DOSE-END>
